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Abstract: Telomerase reverse transcriptase (TERT) is the reverse transcriptase component of the telomeric complex, 
which synthesizes terminal DNA to protect chromosomal ends and to maintain genomic integrity. In melanoma, mu-
tation in TERT promoter region is a common event and theses promoter variants have been shown to be associated 
with increased gene expression, decreased telomere length and poorer outcome. In this study, we determined the 
frequency of TERT promoter mutation in 88 Korean primary melanoma patients and aimed to see the association 
of TERT promoter mutation status to other major molecular features, such as BRAF, NRAS, KIT mutations and cor-
relate with clinicopathological features. In our study, acral melanoma (n=46, 52.3%) was the most common type. 
Overall, TERT promoter mutation was observed in 15 cases (17%) with ten c. -124C>T altertions and five c. -146C>T 
alterations. None of our samples showed CC>TT mutation which is considered pathognomonic of UV induction. 
Among the 46 acral melanoma patients, 5 patients (10.9%) harbored TERT promoter mutation. Tumors with TERT 
promoter mutation showed significantly greater Breslow thickness compared to WT tumors (P=0.039). A combined 
analysis for the presence of TERT promoter and BRAF mutations showed that patients with both TERT promoter 
and BRAF mutation showed decreased survival compared with those with only TERT promoter mutation, only BRAF 
mutation, or without mutations in either TERT promoter or BRAF (P=0.035). Our data provides additional evidence 
that UV-induced TERT promoter mutation frequencies vary depending on melanoma subtype, but preserves its 
prognostic value. 
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Telomerase reverse transcriptase (TERT) is the 
reverse transcriptase component of the telo-
meric complex, which synthesizes terminal 
DNA to protect chromosomal ends and to main-
tain genomic integrity. Its upregulation has 
been demonstrated in several human cancers, 
and the promoter region of the gene is consid-
ered the critical regulatory element for telomer-
ase expression. Mutually exclusive -124C>T 
and -146C>T mutations in TERT promoter re- 
gion have been detected in more than 65% of 
melanomas [1]. These promoter variants have 
been shown to be associated with increased 
gene expression, decreased telomere length 
and poorer outcome [2, 3].
Here we intend to determine the frequency of 
TERT promoter mutation in 88 Korean primary 
melanoma patients who were followed at 
Severance hospital in Seoul, Korea during the 
period from 2005 to 2012 (Supplementary 
Table 1). Furthermore, we aimed to see the 
association of TERT promoter mutation status 
to other major molecular features, such as 
BRAF, NRAS, KIT mutations and correlate with 
clinicopathological features. The study was 
approved by the Institutional Review Board of 
Yonsei University College of Medicine. Written 
informed consent was obtained from all partici-
pants or their legal guardians. DNA was extract-
ed from formalin-fixed, paraffin-embedded tu- 
mor tissues. Genomic DNA was isolated using 
proteinase K digestion and boiling method. 
Polymerase chain reaction (PCR) amplification 
of the TERT promoter region was performed 
using primers 5’-CCCACGTGCGCAGCAGGAC-3’ 
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Figure 1. A. TERT promoter mutation variants identified in acral melanoma. B. Kaplan-Meier curves for overall sur-
vival according to TERT promoter mutation status. Kaplan-Meier survival analysis showed no association of TERT 
promoter mutation status with patient survival (P=0.928). C. Kaplan-Meier curves for overall survival in patients with 
both TERT promoter and BRAF mutation. Patients with both TERT promoter and BRAF mutation showed decreased 
survival compared with those with only TERT promoter mutation , only BRAF mutation, or without mutations in either 
TERT promoter or BRAF (P=0.035).
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Table 1. Associations of TERT mutation with clinical and 









    Mean 60.2 57 0.415
Gender 
    Male 34 (46.6) 10 (66.7) 0.156
    Female 39 (53.4) 5 (33.3)
Stage at diagnosis (%)*
    0/I/II 43 (58.9) 9 (60) 0.937
    III/IV 30 (41.1) 6 (40)
Subtype (%)
    Acral 41 (89.1) 5 (10.9) 0.389
    Mucosal 7 (87.5) 1 (12.5)
    CSD 8 (66.7) 4 (33.3)
    Non-CSD 14 (77.8) 4 (22.2)
    UP 3 (75) 1 (25)
Mutant Oncogene
    BRAF V600E 10/67 (14.9) 4/14 (28.5) 0.219
    NRAS 6/68 (8.8) 1/14 (7.1) 0.526
    KIT 6/50 (12) 3/11 (27.3) 0.39
Breslow thickness (mm)
    Median 2.35 5 0.039
    Range 0.6-15 0.4-27
    0.01-1.00 11 (19.6) 2 (18.2)
    1.01-2.00 12 (21.4) 2 (18.2)
    2.01-4.00 11 (19.6) 0 (0)
    >4.00 22 (39.3) 7 (63.6)
Anatomic sites of tumors
    Trunk 5 (83.3) 1 (16.7) 0.477
    Extremities 51 (85) 9 (15)
    Head and neck 8 (66.7) 4 (33.3)
    Other 7 (87. 5) 1 (12.5)
*Staging according to the American Joint Committee on Cancer (AJCC) 
Melanoma Staging System 2009.
(forward), 5’-Biotin-CTCCCAGTGGATTCGCGGG- 
C-3‘ (reverse) and 5’-AGGGGCTGGGAGGGC (se- 
quencing). PCR products were used as templa-
tes for pyrosequencing with PyroMark Gold 
Q24 reagent (Qiagen, Germantown, MD, USA) 
according to the manufacture’s protocol. Se- 
quencing analysis was performed using Pyro- 
Mark Q24 version 1.0.10 software in the allele 
quantification analysis mode. For statistical 
analysis, categorical data are described using 
frequencies and percentages, and continuous 
data are described using means ± standard 
deviations or median (range) for normally dis-
followed by head and neck area (n=12), other 
including mucosa (n=8), and trunk (n=6). Acral 
melanoma (n=46) was the most common type, 
followed by non-CSD (chronic sun-damage) 
melanoma (n=18), CSD melanoma (n=12), 
mucosal melanoma (n=8), and melanoma of 
unknown primary (n=4). Breslow tumor thick-
ness ranged from 0.3 to 27 mm, with a median 
of 2.5 mm. BRAF mutations were detected in 
14 tumors (15.9%), NRAS mutations in 10 
cases (11.4%), and KIT mutations in 9 speci-
mens (10.2%). TERT promoter variants were 
identified in 15 cases (17%) with ten c. -124C>T 
tributed data. Chi-squared (χ2) test or 
Fisher’s exact test was used to differen-
tiate the rates of different groups, and 
differences in measurement data of 2 
groups were evaluated by unpaired 
t-test or Mann-Whitney test. We used 
univariate logistic regression analyses 
to explore associations of TERT promot-
er mutation status with available clinical 
and pathologic variables, including age, 
sex, stage, oncogene mutation status, 
anatomical distribution of primary 
tumor, Breslow’s thickness, and ulce- 
ration. 
We investigated association between 
clinico-pathologic factors, TERT promot-
er mutation status, and oncogene muta-
tion status with overall survival, defined 
as the interval from time of diagnosis of 
primary melanoma to death. Cases in 
which the endpoint was not reached at 
the time of the last follow-up were cen-
sored. Univariate results were displayed 
by the Kaplan-Meier method and hazard 
ratio estimates and p-values were 
derived from Cox proportional hazard 
model. Multivariable analyses were per-
formed on variables with a p-value of 
0.20 or less in univariate analyses. 
Confidence intervals (CI) were calculat-
ed with coverage of 95%. All reported 
p-value are nominal and two-sided. We 
applied a significance level of 5%. All 
statistical analyses were performed 
using SPSS Statistics software (version 
18.0; SPSS Chicago, IL) or R 3.1.1.
The median age at diagnosis was 59 
years (range 28-87 years) with equal 
male and female patients (M:F=44:44). 
Extremities (n=60) was the most com-
mon location of the primary melanoma, 
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altertions and five c. -146C>T alterations. 
Among ther 46 acral melanoma patients, 5 
patients (10.9%) harbored TERT promoter 
mutation. Three cases were c. -124C>T alterti-
ons and two cases were c. -146C>T alterations 
(Figure 1A). The clinical and pathologic charac-
teristics of tumors with regard to TERT promot-
er mutation status are detailed in Table 1. 
There were no significant differences in age, 
gender, stage at diagnosis, subtype, oncogene 
mutation status, or anatomic site of tumor. 
However, tumors with TERT promoter mutation 
showed significantly greater Breslow thickness 
compared to WT tumors (P=0.039). TERT pro-
moter mutations were observed in 33.3% of 
CSD melanoma, 22.2% of non-CSD melanoma, 
12.5% of mucosal melanoma and 10.9% of 
acral melanoma. Four patients were identified 
to have both BRAF and TERT promoter mutati-
on. Survival analyses were performed for all 
patients (Supplementary Table 2). Univariate 
predictors of survival were gender (P=0.019), 
Breslow thickness (P=0.003), stage at diagno-
sis (P<0.001), and BRAF mutation (P=0.001). 
Kaplan-Meier survival analysis showed no 
association of TERT promoter mutation status 
with patient survival (P=0.928, Figure 1B). 
Multivariable analysis indicated that stage 
at diagnosis (HR=4.328, 95% CI: 2.5-7.5; 
P<0.001) was the only independent factor 
associated with survival in our cohort. A com-
bined data analysis for the presence of TERT 
promoter and BRAF mutations showed that the 
patients with both TERT promoter and BRAF 
mutation showed decreased survival compared 
with those with only TERT promoter mutation , 
only BRAF mutation, or without mutations in 
either TERT promoter or BRAF (P=0.035, Figure 
1C).
In this study carried out on patients with prima-
ry melanoma, the simultaneous occurrence of 
TERT promoter and BRAF mutations was asso-
ciated with decreased survival in Korean mela-
noma patients. TERT promoter mutation has 
been reported to be associated with older 
patients, increased Breslow thickness, and 
worse prognosis in simultaneous occurrence 
with BRAF mutation which was in line with our 
study [4]. Overall, TERT promoter mutation was 
observed in 17% of the patients, which is much 
lower than previous reports showing up to 65% 
of the patients [1, 3, 4]. Huang et al. screened 
whole-genome sequencing data of melanoma 
and found that, apart from mutations in BRAF 
and NRAS, recurrent TERT promoter mutations 
were the most frequent genomic alteration [2]. 
The possible explanation of low incidence of 
TERT promoter mutation in our study may be 
due to the difference in the subtypes of mela-
noma in our cohort. It is well-known that acral 
melanoma is the most frequent type of mela-
noma in Asian patients [5]. In our study, acral 
and mucosal melanoma consisted of 61.4% of 
our patients. In acral melanoma, TERT promot-
er mutation was present in only 10.9% which is 
in line with previous studies reporting that TERT 
promoter mutation is uncommon in acral mela-
noma compared to non-acral melanoma [6]. 
Second possible reason is that our cohort of 
samples was all primary melanomas. Horn et 
al. detected TERT promoter mutations in 33% 
of primary melanomas and at considerably 
higher frequencies in melanoma cell lines (74%) 
and corresponding tissue from metastasis 
(85%) [2]. Dipyrimidine CC>TT mutations are 
considered pathognomonic of UV induction [7]. 
In our study, none of our samples showed 
CC>TT mutation, and TERT promoter mutations 
were considerably more frequent in nonacral 
cutaneous melanomas than acral melanomas. 
In the literature, there were only 16 cases 
(including 5 cases in our study) [6, 8-10] of 
acral melanoma which harbor TERT promoter 
mutations and none of the cases had shown 
CC>TT mutation (Figure 1A). This finding is con-
sistent with a role for UV-induction in the patho-
genesis, as acral sites are rarely sun-exposed 
and further supported by the absence of UV 
signature mutations, particularly CC>TT. Our 
data provides additional evidence that 
UV-induced TERT promoter mutation frequen-
cies vary depending on melanoma subtype, but 
preserves its prognostic value.
Acknowledgements
This work was made possible by a grant from 
the NIH (K24 CA149202 to HT), a grant from 
the Basic Science Research Program through 
the National Research Foundation of Korea, 
which is funded by the Ministry of Education, 
Science, and Technology (2011-0022376 to 
MRR), a grant of the Korea Health Technology 
R&D Project through the Korea Health Industry 
Development Institute (KHIDI), funded by the 
Ministry of Health & Welfare, Republic of Korea 
(HI13C2096 to SYR) and the generous donors 
to the MGH Millennium Melanoma Fund and 
Innovations in Melanoma Care Fund.
TERT mutation in Korean melanoma patients
138 Am J Cancer Res 2017;7(1):134-138
Disclosure of conflict of interest
None.
Address correspondence to: Dr. Hensin Tsao, De- 
partment of Dermatology, Massachusetts General 
Hospital, Harvard Medical School, Boston, MA 
02114, USA. Tel: 1-617-726-2914; E-mail: htsao@
mgh.harvard.edu; Dr. Sun Young Rha, Division of 
Medical Oncology, Department of Internal Medicine, 
Yonsei University College of Medicine, 50 Yonsei-ro, 
Seodaemoon-gu, Seoul 03722, Korea. Tel: 82-2-
2228-8050; E-mail: RHA7655@yuhs.ac
References
[1] Cancer Genome Atlas Network. Genomic 
Classification of Cutaneous Melanoma. Cell 
2015; 161: 1681-1696.
[2] Horn S, Figl A, Rachakonda PS, Fischer C, 
Sucker A, Gast A, Kadel S, Moll I, Nagore E, 
Hemminki K, Schadendorf D and Kumar R. 
TERT promoter mutations in familial and spo-
radic melanoma. Science 2013; 339: 959-
961.
[3] Nagore E, Heidenreich B, Rachakonda S, 
Garcia-Casado Z, Requena C, Soriano V, Frank 
C, Traves V, Quecedo E, Sanjuan-Gimenez J, 
Hemminki K, Teresa Landi M and Kumar R. 
TERT promoter mutations in melanoma sur-
vival. Int J Cancer 2016; 139: 75-84.
[4] Griewank KG, Murali R, Puig-Butille JA, Schilling 
B, Livingstone E, Potrony M, Carrera C, 
Schimming T, Moller I, Schwamborn M, Sucker 
A, Hillen U, Badenas C, Malvehy J, Zimmer L, 
Scherag A, Puig S and Schadendorf D. TERT 
promoter mutation status as an independent 
prognostic factor in cutaneous melanoma. J 
Natl Cancer Inst 2014; 106.
[5] Chang JW. Acral melanoma: a unique disease 
in Asia. JAMA Dermatol 2013; 149: 1272-
1273.
[6] Liau JY, Tsai JH, Jeng YM, Chu CY, Kuo KT and 
Liang CW. TERT promoter mutation is uncom-
mon in acral lentiginous melanoma. J Cutan 
Pathol 2014; 41: 504-508.
[7] Pleasance ED, Cheetham RK, Stephens PJ, 
McBride DJ, Humphray SJ, Greenman CD, 
Varela I, Lin ML, Ordonez GR, Bignell GR, Ye K, 
Alipaz J, Bauer MJ, Beare D, Butler A, Carter RJ, 
Chen L, Cox AJ, Edkins S, Kokko-Gonzales PI, 
Gormley NA, Grocock RJ, Haudenschild CD, 
Hims MM, James T, Jia M, Kingsbury Z, Leroy C, 
Marshall J, Menzies A, Mudie LJ, Ning Z, Royce 
T, Schulz-Trieglaff OB, Spiridou A, Stebbings 
LA, Szajkowski L, Teague J, Williamson D, Chin 
L, Ross MT, Campbell PJ, Bentley DR, Futreal 
PA and Stratton MR. A comprehensive cata-
logue of somatic mutations from a human can-
cer genome. Nature 2010; 463: 191-196.
[8] de Lima Vazquez V, Vicente AL, Carloni A, 
Berardinelli G, Soares P, Scapulatempo C, 
Martinho O and Reis RM. Molecular profiling, 
including TERT promoter mutations, of acral 
lentiginous melanomas. Melanoma Res 2016; 
26: 93-99.
[9] Heidenreich B, Nagore E, Rachakonda PS, 
Garcia-Casado Z, Requena C, Traves V, Becker 
J, Soufir N, Hemminki K and Kumar R. 
Telomerase reverse transcriptase promoter 
mutations in primary cutaneous melanoma. 
Nat Commun 2014; 5: 3401.
[10] Vinagre J, Almeida A, Populo H, Batista R, Lyra 
J, Pinto V, Coelho R, Celestino R, Prazeres H, 
Lima L, Melo M, da Rocha AG, Preto A, Castro 
P, Castro L, Pardal F, Lopes JM, Santos LL, Reis 
RM, Cameselle-Teijeiro J, Sobrinho-Simoes M, 
Lima J, Maximo V and Soares P. Frequency of 
TERT promoter mutations in human cancers. 
Nat Commun 2013; 4: 2185.
TERT mutation in Korean melanoma patients
1 
Supplementary Table 1. Clinical characteris-
tics of enrolled melanoma patients
Characteristics N (%)
Patient No. (%) 88 (100)
Age (year)
    Median (Range) 59 (28-87)
Gender 
    Male:Female 44:44
Stage at diagnosis (%)*
    0/I/II 52 (59.1)
    III/IV 36 (0.934.5)
Subtype (%)
    Acral 46 (52.3)
    Mucosal 8 (9.1)
    CSD 12 (13.6)
    Non-CSD 18 (20.5)
 Unknown primary 4 (4.5)
Mutant Oncogene
    BRAF 14 (15.9)
    NRAS 10 (11.4)
    KIT 9 (10.2)
TERT promoter mutations†
    All mutations 15/88 (17)
    124C>T 10/88 (11.4)
    138_139CC>TT 0/88 (0)
    146C>T 5/88 (5.6)
Breslow thickness (mm)
    Median (Range) 2.5 (0.3-27)
    0.01-1.00 13 (14.8)
    1.01-2.00 14 (15.9)
    2.01-4.00 11 (12.5)
    >4.00 29 (33)
Anatomic sites of tumors
    Trunk 6 (6.8)
    Extremities 60 (68.2)
    Head and neck 12 (13.6)
    Other 8 (9.1)
Sample type sequenced
    Primary 84 (1800)
    Metastasis 0 (0)
*Staging according to the American Joint Committee on 
Cancer (AJCC) Melanoma Staging System 2009. †Muta-
tions are annotated applying the last three digits of the 
first nucleotide mutated in the chromosome location 
according to hg19: Chr.5: 1295xxx (where xxx is a place 
holder for the mutation number).
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Supplementary Table 2. Univariate and Multivariate Cox-Regression Analyses for Overall survival
 Risk factors Univariable  Multivariable
  HR 95% CI P value HR 95% CI P value
Definite event Age (by 1 yr increment) 1.014 0.997-1.032 0.116 1.012 0.992-1.032 0.230 
Sex (vs female) 1.783 1.100-2.889 0.019 
Thickness 1.091 1.031-1.155 0.003 
Stage III or IV (vs. I or II) 4.597 2.802-7.544 0.000 4.328 2.492-7.516 0.000 
Tumor site 0.484 
Extremities vs others 0.498 0.208-1.189 0.116 
BRAF 2.619 1.481-4.634 0.001 1.493 0.815-2.737 0.195 
NRAS 0.768 0.359-1.689 0.511 
 TERT 0.963 0.425-2.181 0.928     
For multivariable analyses, variables with a P value of 0.20 or less in univariable analyses were candidates for the multivari-
able Cox models. Independent predictors from baseline demographic and clinical variables were determined by multivariable 
Cox-regression analyses. Influences of “Genetic aberration” on overall survival were analyzed by adjustment for independent 
predictors determined by multivariable analyses. 
